AbbVie's Qulipta has become the first oral CGRP inhibitor to show efficacy in a phase 3 study involving women with menstrual ...
The National Commission into the Regulation of AI in Healthcare has delivered its keenly anticipated report, which gives ...
Jiangsu Hengrui Pharma's oral thrombopoietin (TPO) receptor agonist hetrombopag has been approved in China to treat low ...
Right after reporting encouraging data with its Dravet syndrome gene therapy, Encoded Therapeutics has raised an impressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results